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Abstract	
Findings from a recent study of the largest documented cohort of individuals with Down syndrome
(DS) in the United States described prevalence of common disease conditions and strongly suggested
significant disparity in mental health conditions among these individuals as compared with age- and
sex-matched individuals without DS. The retrospective, descriptive study reported herein is a follow-up
to document prevalence of 58 mental health conditions across 28 years of data from 6078 individuals
with DS and 30,326 age- and sex-matched controls. Patient data were abstracted from electronic
medical records within a large integrated health system.
In general, individuals with DS had higher prevalence of mood disorders (including depression);
anxiety disorders (including obsessive-compulsive disorder); schizophrenia; psychosis (including
hallucinations); pseudobulbar affect; personality disorder; dementia (including Alzheimer’s disease);
mental disorder due to physiologic causes; conduct disorder; tic disorder; and impulse control disorder.
Conversely, the DS cohort experienced lower prevalence of bipolar I disorder; generalized anxiety,
panic, phobic, and posttraumatic stress disorders; substance use disorders (including alcohol, opioid,
cannabis, cocaine, and nicotine disorders); and attention-deficit/hyperactivity disorder. Prevalence of
many mental health conditions in the setting of DS vastly differs from comparable individuals without
DS. These findings delineate a heretofore unclear jumping-off point for ongoing research. (J Patient
Cent Res Rev. 2022;9:58-63.)
Keywords	Down syndrome; prevalence; mental health; depression; anxiety; dementia; substance use; ADHD

A

recent study of the largest documented cohort
of individuals with Down syndrome (DS) in
the United States described the prevalence
of a broad range of disease conditions.1 Findings
strongly suggested significant disparity in mental health
conditions, in particular, among individuals with DS
as compared with age- and sex-matched individuals
without DS.1 Previous research has shown that, overall,
people with DS seem to be more vulnerable to mental
health issues and diagnosis;2-4 however, some experts
believe overdiagnosis is common due to deficits in
language, communication, cognition, problem-solving,
and coping.5 Regardless, given that the prevalence of DS
itself is increasing6 and that the lifespan for individuals
with DS has grown in recent decades,7-11 a more in-

depth analysis of mental health conditions among this
patient population is merited, not only for foundational
knowledge but also to facilitate better diagnostics and
clinical care.
To explore rates of mental health conditions among
individuals with DS, this study utilizes clinical data
representing the largest reported DS sample cohort in
the United States, treated across a single integrated
health system that includes the largest center of care
for adolescents and adults with DS. The objective of
this follow-up brief report to a broader study1 was to
provide critical information on mental health conditions
in individuals with DS in order to better guide general
practitioners, enhance specialized care, and inform future
research within this unique population.

METHODS

Corresponding author: Anne Rivelli,
Advocate Lutheran General Hospital, 1775 Dempster St.,
Suite W-939, Park Ridge, IL 60068 (anne.rivelli@aah.org)
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This retrospective, descriptive cohort study utilized 28
years of available encounter data (May 1991–September
2019) abstracted from the electronic medical records
of an integrated U.S. Midwest-based nonprofit health
Brief Report

system. As a follow-up to a larger study conducted with
this patient population, it was determined to be nonhuman subjects research by the applicable institutional
review board. Full details on the data collection methods
for this and the more generalized prevalence study can be
found in the previously published primary report.1
Participants

A total of 6078 eligible cases, ranging in age from 0
to 89 years, with at least 1 encounter registering an
International Classification of Diseases (ICD) code of
DS were identified. Controls included up to 5 individuals
without a diagnosis of DS matched to each DS case on
year of birth (±1 year) and sex by a data analyst. There
were 30,326 eligible controls. Overall, 64 cases were
assigned only 4 (as opposed to 5) matched controls.
Procedures

Specific mental health conditions of interest among
individuals with DS were preidentified. Conditions
were chosen based on both the literature and the clinical
expertise of one of the study authors (B.C.). To assess
prevalence, this study used U.S. Clinical Modification
(CM) codes for medical diagnoses based on the statistical
classification of disease denoted in the World Health
Organization’s publication of the ICD,12 specifically, 10th
Revision (ICD-10-CM) and 9th Revision (ICD-9-CM)
codes. See Table 1 for a complete list of mental health
conditions of interest and associated ICD codes.
Statistical Methods

Demographics are reported as means with standard
deviations and medians with ranges for age and total
encounters per sample. Sex, race, ethnicity, and insurance
are reported as counts with percentages. Clinical
conditions are reported as counts with percentages and
corresponding odds ratios (OR) representing the odds of
having a mental health condition among cases relative to
controls. Corresponding Pearson’s chi-squared P-values
represent statistically significant (at an alpha of <0.05)
differences in prevalence of diagnoses between cases and
controls. Fisher’s exact P-values were interpreted when
any sample count was less than 5.

RESULTS

The cohort of DS cases was predominantly White (77.35%)
and of non-Hispanic or Latino ethnicity (73.51%). Cases
had a median of 6 total encounters (ie, clinical visits in
the health system) in the dataset. The control cohort also
was predominantly White (61.97%) and of non-Hispanic
or Latino ethnicity (81.72%), with a median of 7 total
encounters in the dataset. Both groups were approximately
52% male and had a median age of 25 years. For complete
demographics of the DS and matched control samples, the
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reader is referred to the relevant table published within
the parent article describing this project.1
The following findings describe the OR and 95% CI along
with associated P-value when comparing prevalence of
a mental health conditions of interest among individuals
with DS (ie, cases) to matched controls. See Table 2 for
full results.
Statistically significant results revealed that, relative
to controls, individuals with DS had greater odds of
experiencing: any mood disorder (OR: 3.41 [2.85, 4.07];
P<0.0001) and, specifically, depression (OR: 1.27 [1.15,
1.39]; P<0.0001); any anxiety disorder (OR: 1.09 [1.01,
1.17]; P=0.0206) and, specifically, obsessive-compulsive
disorder (OCD) (OR: 20.15 [16.43, 24.71]; P<0.0001);
schizophrenia (OR: 1.87 [1.17, 3.00]; P=0.0077); any
psychosis (OR: 3.87 [2.27, 6.61]; P<0.0001) and,
specifically, hallucinations (OR: 2.35 [1.30, 4.26];
P=0.0037); pseudobulbar affect (OR: 49.98 [6.40,
390.47]; P<0.0001); any personality disorder (2.58 [1.69,
3.93]; P<0.0001) and, specifically, other or unspecified
personality disorders (OR: 6.00 [3.02, 11.92]; P<0.0001);
dementia (OR: 17.13 [13.39, 21.90]; P<0.0001) and,
specifically, Alzheimer’s disease (OR: 66.97 [50.39,
88.99]; P<0.0001); mental disorders due to physiologic
causes (OR: 2.94 [1.69, 5.11]; P<0.0001); conduct
disorders (OR: 2.01 [1.60, 2.53]; P<0.0001); tic disorders
(OR: 1.67 [1.21, 2.31]; P=0.0018); and impulse control
disorder (OR: 23.03 [13.40, 39.59]; P<0.0001).
On the other hand, statistically significant results
revealed that, relative to controls, individuals with DS
have lesser odds of experiencing: bipolar I (OR: 0.49
[0.27, 0.89]; P=0.0174); generalized anxiety disorder
(OR: 0.25 [0.17, 0.38]; P<0.0001); panic disorder (OR:
0.07 [0.03, 0.18]; P<0.0001); phobic anxiety disorder
(OR: 0.55 [0.35, 0.88]; P=0.0109); posttraumatic stress
disorder (PTSD) (OR: 0.60 [0.39, 0.91]; P=0.0143); any
substance use disorder (OR: 0.08 [0.06, 0.10]; P<0.0001)
and, specifically, alcohol use (OR: 0.04 [0.02, 0.08];
P<0.0001), opioid use (OR: 0.12 [0.04, 0.31]; P<0.0001),
cannabis use (OR: 0.04 [0.01, 0.15]; P<0.0001), cocaine
use (OR: 0.18 [0.06, 0.56]; P=0.0003), other stimulant
use (OR: 0.08 [0.04, 0.19]; P<0.0001), and nicotine use
disorders (OR: 0.08 [0.06, 0.11]; P<0.0001); and, finally,
attention-deficit/hyperactivity disorder (ADHD) (OR:
0.58 [0.48, 0.69]; P<0.0001).

DISCUSSION

Our results corroborate previous research that shows
prevalences of mental health conditions in individuals
with DS are vastly different relative to their non-DS
matched counterparts.3,4,13 Importantly, these mental
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Table 1. Mental Health Conditions of Interest and Associated Codes
Mental health condition

ICD-10-CM codes

ICD-9-CM codes

F39
F30
F31
F310–F3178
F3181
F340
F3189, F319
F32–F33

296, 2969
2961
2960, 2964, 2965, 2966, 2967, 2968
2960, 2964, 2965, 2966, 2967
29689
30113
2968
2962, 2963, 311

F40–F48
F411
F401
F410
F40
F431
F42

300
30002
30023
30001, 30021
3002
30981
3003

Mood disorders
Manic episode(s)
Bipolar disorders
Bipolar I
Bipolar II
Cyclothymic disorder/cyclothymia
Bipolar disorder, other/unspecified
Depression
Anxiety disorders
Generalized anxiety disorder
Social phobias
Panic disorder
Phobic anxiety disorder
Posttraumatic stress disorder
Obsessive compulsive disorder
Schizophrenia

F20

295

Schizoaffective disorder

F25

2957

F23
R440–R443
F22

298
7801
297

F44, F4481, F481
F440
F481
F4481

3001, 30012, 30014, 3006
30012
3006
30014

F482

31081

F60
F603
F600
F601
F602
F604
F605
F606
F607
F6081
F6089, F609

301
30183
3010
3012
3017
3015, 30150, 30159
3014
30182
3016
30181
30189, 3019

Substance use/abuse
Alcohol
Opioid
Cannabis
Sedative, hypnotic, anxiolytic
Cocaine
Other stimulant
Hallucinogen
Nicotine
Inhalant
Other psychoactive

F10–F19
F10
F11
F12
F13
F14
F15
F16
F17
F18
F19

303–305
303, 3050
3040, 3055
3043, 3052
3041
3042, 3056
3044, 3054
3045, 3053
3051
–
3046, 3049

Dementia
Alzheimer’s disease

F02–F03
G30

2900, 29420
3310

F06

2939

F50
F500
F502
F5081

3075
3071
30751
–

Psychosis
Hallucinations
Delusion disorders
Dissociative disorders
Dissociative amnesia
Depersonalization disorder
Dissociative identity disorder
Pseudobulbar affect
Personality disorder
Borderline
Paranoid
Schizoid
Antisocial
Histrionic
Obsessive compulsive
Avoidant
Dependent
Narcissistic
Other/Unspecified

Mental disorders to due physiologic cause
Eating disorders
Anorexia nervosa
Bulimia nervosa
Binge eating disorder
Conduct disorders

F91

312

Attention-deficit/hyperactivity disorder

F90

31401

Tic disorders

F95

30720

Impulse control disorder

F639

3123

CM, Clinical Modifications; ICD, International Classification of Diseases.
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Table 2. Prevalence of Mental Health Conditions of Interest Among Cases vs Controls
Mental health condition

DS sample (n=6078)

Controls (n=30,326)

OR (95% CI)

Pa

208
0
99
12
3
0
90
571
1029
24
5
5
20
25
447
24
12
24
16
6
11
0
0
0

312
9
435
121
32
9
372
2297
4773
474
49
332
180
208
119
64
49
31
34
13
37
0
0
3

3.41 (2.85, 4.07)
–
1.14 (0.91, 1.42)
0.49 (0.27, 0.89)
0.47 (0.14, 1.53)
–
1.21 (0.96, 1.53)
1.27 (1.15, 1.39)
1.09 (1.01, 1.17)
0.25 (0.17, 0.38)
0.51 (0.20, 1.28)
0.07 (0.03, 0.18)
0.55 (0.35, 0.88)
0.60 (0.39, 0.91)
20.15 (16.43, 24.71)
1.87 (1.17, 3.00)
1.22 (0.65, 2.30)
3.87 (2.27, 6.61)
2.35 (1.30, 4.26)
2.30 (0.88, 6.06)
1.48 (0.76, 2.91)
–
–
–

<0.0001
0.3721b
0.2499
0.0174
0.2584b
0.3721b
0.1063
<0.0001
0.0206
<0.0001
0.1425
<0.0001
0.0109
0.0143
<0.0001
0.0077
0.5328
<0.0001
0.0037
0.0819
0.2475
–
–
1.0000b

Pseudobulbar affect

10

1

49.98 (6.40, 390.47)

<0.0001b

Personality disorder
Borderline
Paranoid
Schizoid
Antisocial
Histrionic
Obsessive-compulsive
Avoidant
Dependent
Narcissistic
Other/Unspecified
Substance use/abuse
Alcohol
Opioid
Cannabis
Sedative, hypnotic, anxiolytic
Cocaine
Other stimulant
Hallucinogen
Nicotine
Inhalant
Other psychoactive
Dementia
Alzheimer's disease

33
1
0
0
0
0
2
0
1
0
18
76
9
4
2
2
3
6
0
51
0
0
276
627

64
27
0
0
3
0
10
0
3
3
15
4095
1016
172
274
37
85
354
9
2896
0
0
84
52

2.58 (1.69, 3.93)
0.18 (0.03, 1.36)
–
–
–
–
1.00 (0.22, 4.56)
–
–
–
6.00 (3.02, 11.92)
0.08 (0.06, 0.10)
0.04 (0.02, 0.08)
0.12 (0.04, 0.31)
0.04 (0.01, 0.15)
0.27 (0.06, 1.12)
0.18 (0.06, 0.56)
0.08 (0.04, 0.19)
–
0.08 (0.06, 0.11)
–
–
17.13 (13.39, 21.90)
66.97 (50.39, 88.99)

<0.0001
0.0732b
–
–
1.0000b
–
1.0000b
–
–
1.0000b
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001b
0.0527b
0.0003b
<0.0001
0.3721b
<0.0001
–
–
<0.0001
<0.0001

Mental disorders due to physiologic cause

20

34

2.94 (1.69, 5.11)

<0.0001

Eating disorders
Anorexia nervosa
Bulimia nervosa
Binge eating disorder

17
1
1
0

71
10
16
5

1.20 (0.70, 2.03)
0.50 (0.06, 3.90)
0.31 (0.04, 2.35)
1.00 (0.12, 8.54)

0.5090
0..7038b
0. 3378b
1.0000b

Conduct disorders
Attention-deficit/hyperactivity disorder
Tic disorders
Impulse control disorder

104
144
49
73

260
1223
147
16

2.01 (1.60, 2.53)
0.58 (0.48, 0.69)
1.67 (1.21, 2.31)
23.03 (13.40, 39.59)

<0.0001
<0.0001
0.0018
<0.0001

Mood disorders
Manic episode(s)
Bipolar disorder
Bipolar I
Bipolar II
Cyclothymic disorder/Cyclothymia
Bipolar disorder, other/unspecified
Depression
Anxiety disorders
Generalized anxiety disorder
Social phobias
Panic disorder
Phobic anxiety disorder
Posttraumatic stress disorder
Obsessive-compulsive disorder
Schizophrenia
Schizoaffective disorder
Psychosis
Hallucinations
Delusion disorders
Dissociative disorders
Dissociative Amnesia
Depersonalization disorder
Dissociative identity disorder

a

Statistical significance was reached at an alpha of <0.05.

b

Fisher’s exact test P-value was interpreted due to low sample count.

DS, Down syndrome; OR, odds ratio.
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health prevalence findings provide a baseline jumping-off
point for ongoing research in DS settings. They also may
compel actions for remodeled care specific to individuals
with DS. A deeper investigation into the broad range of
highly prevalent mental health conditions — along with
the coexisting physical disorders that may contribute
to their development — is merited to increase our
understanding of how these conditions impact this patient
population. The unique assessment and treatment barriers
often faced by those with DS could be improved through
more refined screening tools and treatment protocols.
While study findings represent data from only one U.S.
health system, this rather large system of 26 hospitals and
more than 500 outpatient locations may provide the most
accurate and available review of prevalence among a
U.S. sample, given the United States’ fragmented storage
of patient data. Furthermore, much of the data came from
a specialized care center specifically serving adults with
DS, which may improve diagnostic accuracy of ICD
coding and subsequent prevalence findings. It should be
noted that diagnostic accuracy in general can be difficult
with individuals with DS for a variety of reasons.14
In general, diagnosis of mental health conditions
with behavioral components can be inaccurate among
individuals with DS.15,16 For instance, overlapping
symptoms, like sensory or motor deficits, and other
common comorbid medical conditions, like thyroid
problems and sleep apnea, may mimic dementia or
depression, affecting diagnosis.4,15 While our study showed
increased prevalence of depression, a previous study
found that half of patients with DS who were diagnosed
with depression were found to not meet official diagnostic
criteria, signifying a need for separate diagnostic criteria
for patients with developmental disabilities.17
Research has also suggested that youth with DS are more
likely to show externalizing behaviors than siblings and
peers without DS.4,18,19 To this end, individuals with DS
have shown increased prevalence of ADHD, conduct
disorder, and anxiety disorder diagnoses, possibly
reflecting increased diagnosis patterns versus true disease
prevalence.3,4 While our study showed higher prevalence
of conduct and anxiety disorders among individuals with
DS, it also showed lesser prevalence of ADHD.
It has been noted that externalizing behaviors seen in
youth with DS change into internalizing behaviors seen
in adolescence and adulthood.3 Prevalence of OCD,
a condition characterized by internalized symptoms
of obsessions and compulsions, has been shown to
range in individuals with DS, attributed to difficulty in
assessment.3,4 However, diagnostic inaccuracies from
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factors like individuals not being able to provide their
own history were not studied in this paper. For example,
while some research has shown PTSD to be more
common in DS due to strong visual memories,20 our
study found it to be less common. A patient’s inability or
limited ability to convey the “trauma” may lead to PTSD
being undiagnosed and perhaps resulting, instead, in only
diagnosis of the symptomatic presentation such as mood
disorder or psychoses, both of which were more common
in this study’s DS cohort.
Contrary to one prior study,21 we found higher prevalence
of schizophrenia in people with DS. While the codes
used to represent the conditions of interest in this study
were carefully chosen and reviewed by a clinical expert
in DS, it is acknowledged that the utilized codes may not
be ones most commonly used to represent corresponding
conditions. It is also possible that these codes over- or
underrepresent diagnoses among individuals with DS
relative to individuals without DS. This may be particularly
true of diagnoses with primarily behavioral criteria.22
Study Limitations

This study did not assess etiology and cause of the mental
illnesses. For example, comorbid mental and physical
health conditions likely impact treatment progress in
both areas, so understanding the relationship between
them is critical in this group. Also, reasons for differences
in mental illness diagnosis, including intrinsic factors
associated with or the genetics of DS, environmental
factors, employment or social activities, and display of
symptoms, were not explored.
While this study included both youths and adults with
DS, future longitudinal analyses are necessary to look at
prevalence of conditions across time, to report on youth
and adult populations separately, and to track the course
of conditions seen at different stages of the lifespan of
individuals with DS, particularly as that lifespan continues
to increase. Due to the diagnostic challenges and limited
literature, we recommend cautious interpretation of
mental illness data in individuals with DS. Future research
should attempt to mitigate these challenges.

CONCLUSIONS

In this mental health-focused follow-up to a previously
published study on the prevalence of common diseases
among individuals with Down syndrome relative to
matched controls,1 it was found that, overall, individuals
with DS are more likely than their non-DS counterparts
to experience a variety of mental health conditions. These
include mood disorders (particularly depression), anxiety
disorders (particularly OCD), schizophrenia, psychosis
and hallucinations, pseudobulbar affect, personality
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disorders (often unspecified), dementia and Alzheimer’s
disease, mental disorders due to physiologic cause,
conduct disorder, tic disorder, and impulse control
disorder. On the other hand, individuals with DS are
much less likely to experience substance use disorders
relative to their non-DS counterparts and therefore may
not require the same frequency or degree of screening.
Patient-Friendly Recap
• Authors collected decades of patient data from a
large health system to compare the prevalence of
numerous mental health diagnoses in individuals
with Down syndrome (DS) to a control cohort
encompassing similar patients without DS.
•S
 ignificant differences between cohorts revealed
that, generally, individuals with DS were more
likely to be diagnosed with mood and personality
disorders, psychosis, and dementia and less likely
to be diagnosed with substance use disorders than
their age- and sex-matched counterparts.
• It is unclear if these differences are due to
diagnostic approach or genuine prevalence; still,
remodeling mental health screening and care
specific to those with DS is necessary.
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